Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis

Gynecologic Oncology

Volumn 124, Issue 2, 2012, Pages 192-198

  Hwang, Wei Ting ^a   Adams, Sarah F ^a   Tahirovic, Emin ^a   Hagemann, Ian S ^a   Coukos, George ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Meta analysis; Ovarian cancer; Prognosis; TIL; Tumor infiltrating lymphocytes

Indexed keywords

ARTICLE; CANCER SURVIVAL; GENETIC HETEROGENEITY; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; META ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; SYSTEMATIC REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84856021596     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.09.039     Document Type: Article

References (37)

1. W.E. Winter, G.L. Maxwell, and C. Tian Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 3621 3627 (Pubitemid 47372600)
2. T.T. Nguyen, J.D. Wright, and M.A. Powell Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer Int J Gynecol Cancer 18 2008 1194 1199
3. L. Zhang, J.R. Conejo-Garcia, and D. Katsaros Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 2003 203 213 (Pubitemid 36077915)
4. K. Hayashi, K. Yonamine, and K. Masuko-Hongo Clonal expansion of T cells that are specific for autologous ovarian tumor among tumor-infiltrating T cells in humans Gynecol Oncol 74 1999 86 92 (Pubitemid 29331172)
5. E. Halapi, Y. Yamamoto, and C. Juhlin Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas Cancer Immunol Immunother 36 1993 191 197 (Pubitemid 23047718)
6. S. Kooi, R.S. Freedman, and J. Rodriguez-Villanueva Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells Lymphokine Cytokine Res 12 1993 429 437 (Pubitemid 24007548)
7. R.D. Dadmarz, A. Ordoubadi, and A. Mixon Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion Cancer J Sci Am 2 1996 263
8. L.E. Kandalaft, D.J. Powell Jr. , N. Singh, and G. Coukos Immunotherapy for ovarian cancer: what's next? J Clin Oncol 29 2011 925 933
9. L.E. Kandalaft, N. Singh, and J.B. Liao The emergence of immunomodulation: combinatorial psychotherapy opportunities for the next decade Gynecol Oncol 116 2010 222 233
10. D.F. Stroup, J.A. Berlin, and S.C. Morton Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group JAMA 283 2000 2008 2012 (Pubitemid 30214957)
11. G.A. Wells, B. Shea, D. O'Connell, J. Peterson, V. Welch, and M. Losos The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses http://www.ohri.ca/programs/clinical-epidemiology/ oxford.asp (accessed July 24, 2011)
12. D.G. Altman Systematic reviews of evaluations of prognostic variables Br Med J 323 2001 224 228
13. M.K.B. Parmar, V. Torri, and L. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815 2834 (Pubitemid 28562978)
14. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188 (Pubitemid 17189972)
15. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558 (Pubitemid 34746062)
16. M. Egger, G.D. Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test Br Med J 315 1997 629 634 (Pubitemid 27387172)
17. C.B. Begg, and M. Mazumdar Operating characteristics of a rank correlation test for publication bias Biometrics 50 1994 1088 1101
18. B.H. Nelson The impact of T-cell immunity on ovarian cancer outcomes Immunol Rev 222 2008 101 116 (Pubitemid 351430376)
19. M.J. Callahan, Z. Nagymanyoki, and T. Bonome Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer Clin Cancer Res 14 2008 7667 7673
20. M.L. Tsiatas, R. Gyftaki, and C. Liacos Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy Int J Gynecol Cancer 19 2009 1329 1334
21. Y. Dogan, G. Erdogan, H.E. Pestereli, B. Tirak, and S. Karaveli Effect of intratumoral lymphocyte density on the disease-free survival and overall survival in malignant epithelial tumors of the ovary Eur J Gynaecol Oncol 30 2009 523 526
22. C.A. Shah, K.H. Allison, R.L. Garcia, H.J. Gray, B.A. Goff, and E.M. Swisher Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer Gynecol Oncol 109 2008 215 219
23. K. Milne, M. Kobel, and S.E. Kalloger Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors PLoS One 4 2009 e6412
24. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Proc Natl Acad Sci USA 102 2005 18538 18543 (Pubitemid 43011261)
25. + T lymphocytes are prognostic factors of human ovarian cancer Proc Natl Acad Sci USA 104 2007 3360 3365 (Pubitemid 46364164)
26. M. Tomsova, B. Melichar, I. Sedlakova, and I. Steiner Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma Gynecol Oncol 108 2008 415 420 (Pubitemid 351174290)
27. L.Y. Han, M.D. Fletcher, and D.L. Urbauer HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma Clin Cancer Res 14 2008 3372 3379
28. N. Leffers, M.J. Gooden, and R.A. de Jong Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer Cancer Immunol Immunother 58 2009 449 459
29. K. Milne, R.O. Barnes, and A. Girardin Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer PLoS One 3 2008 e3409
30. B. Clarke, A.V. Tinker, and C.H. Lee Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss Mod Pathol 22 2009 393 402
31. M. Stumpf, A. Hasenburg, and M.O. Riener Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes Br J Cancer 101 2009 1513 1521
32. S.F. Adams, D.A. Levine, and M.G. Cadungog Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer Cancer 115 2009 2891 2902
33. D.C. Chi, E.L. Eisenhauer, and J. Lang What is the optimal goal of primary cytoreductive surgery for bulky stage IIIc epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103 2006 559 564 (Pubitemid 44602167)
34. E.L. Eisenhauer, N.R. Abu-Rustum, and Y. Sonoda The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer Gynecol Oncol 108 2008 276 281
35. W.J. Hoskins, W.P. McGuire, and M.F. Brady The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am J Obstet Gynecol 170 1994 974 980 (Pubitemid 24157907)
36. I. Alagkiozidis, A. Facciabene, and C. Carpenito Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18 J Transl Med 7 2009 104
37. I. Alagkiozidis, A. Facciabene, and M. Tsiatas Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy J Transl Med 9 2011 77